← Eichor
Study identifier: NCT06037187 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Coagulopathy of Immunodermatologic Diseases

Condition: Autoimmune Bullous Dermatosis  ·  Sponsor: University of Nebraska

PhaseN/A
Planned participants39
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersYes

About this study

This study will examine the coagulation and fibrinolysis profiles of those with autoimmune skin diseases. Blood samples will be collected from participants with active/poorly controlled immune-mediated skin diseases and mild/latent/well-controlled immune-mediated skin diseases. A one-time sample from 15 general dermatology outpatients who do not have a known or suspected diagnosis of bullous diseases, immune-mediated dermatologic condition, or cutaneous malignancy will also be collected to serve as control. Blood samples from both participant populations will be analyzed for coagulation and inflammatory markers and compared. The results of this study may help inform future studies on the utility of analyzing coagulation and fibrinolysis profiles of patients with autoimmune skin diseases.

This description comes directly from the study's public registry record.

Talk to the study team

Megan E Wackel, MS  ·  402-559-3825  ·  megan.wackel@unmc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Nebraska Medical CenterOmaha, Nebraska, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06037187